ストックスクリーナーアプリを入手
1.11
3.48%
-0.04
Senti Biosciences Inc (SNTI) 最新ニュース
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Guidance Update: Is Senti Biosciences Inc stock a good choice for value investorsAnalyst Downgrade & Free Verified High Yield Trade Plans - moha.gov.vn
How sustainable is Senti Biosciences Inc. stock dividend payoutEarnings Miss & High Yield Equity Trading Tips - Улправда
Comparing Longeveron (NASDAQ:LGVN) & Senti Biosciences (NASDAQ:SNTI) - Defense World
Will Senti Biosciences Inc. stock deliver strong dividend growthChart Signals & Growth Focused Stock Pick Reports - ulpravda.ru
Is Senti Biosciences Inc. stock a good choice for value investors2025 Macro Impact & Weekly High Return Stock Forecasts - Bölüm Sonu Canavarı
Will Senti Biosciences Inc. stock outperform value stocks2025 Price Momentum & Low Drawdown Trading Strategies - DonanımHaber
Income Plays: How institutional buying supports Senti Biosciences Inc. stock2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Why Senti Biosciences Inc. stock is rated strong buyQuarterly Performance Summary & Real-Time Chart Pattern Alerts - Bölüm Sonu Canavarı
Why retail investors pile into Senti Biosciences Inc. stock2025 Sector Review & Real-Time Volume Triggers - DonanımHaber
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Does Senti Biosciences Inc. stock trade at a discount to peersMarket Movement Recap & Safe Capital Growth Plans - Улправда
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Senti Biosciences Earnings Notes - Trefis
Senti Biosciences (NASDAQ:SNTI) Rating Increased to Sell at Wall Street Zen - Defense World
Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World
Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - geneonline.com
Senti Biosciences: Understanding the Market Moves - StocksToTrade
Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - Menafn.com
Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Australia
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
Senti Bio price target raised to $13 from $12 at Chardan - TipRanks
Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga
SNTI: SENTI-202 achieved 50% ORR and 42% CR/CRh with deep, durable remissions in R/R AML - TradingView — Track All Markets
Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade
“Smart” NK Cells: Senti Bio’s Logic-Gated Immunotherapy Strikes R/R AML - Inside Precision Medicine
Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com
Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq
Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq
Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML - Nasdaq
Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com
Senti Biosciences Reports Promising Phase 1 Trial Results - TipRanks
Senti Bio’s SENTI-202 shows promising results in AML clinical trial - Investing.com
Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Canada
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - The Manila Times
Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202 - TradingView — Track All Markets
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - marketscreener.com
Is Senti Biosciences Inc a good long term investmentLong-Term Investment Plans & Small Investment Growth Plans - earlytimes.in
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga
5.77%
大文字化:
|
ボリューム (24 時間):